The Wegovy Pill: Oral Semaglutide for Weight Management Explained

Step 1, Starting: what the 1.5 mg tablet is actually doing

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone that signals fullness to the brain, slows the movement of food through the stomach, and damps down appetite between meals. In the injection, semaglutide is delivered subcutaneously once a week. In tablet form, it is co-formulated with an absorption enhancer called SNAC, which allows a small but consistent proportion of the active ingredient to cross the stomach lining into the bloodstream when the tablet is taken correctly.

The 1.5 mg starting dose is designed to settle your system gently, not to produce immediate weight loss. Gastrointestinal side effects (nausea in particular) are most common early on and tend to ease as the body adjusts. Your prescriber sets the pace of titration; the schedule is a clinical decision, not something to accelerate independently. The NHS patient information page for semaglutide covers the side-effect profile in plain language and is a useful first reference alongside your Patient Information Leaflet.

One practical check worth building into your morning: look at the foil pack before you open it. The tablet's date and dose are printed on each blister, so you can confirm at a glance that you have the right strength before swallowing. It takes under ten seconds and removes any guesswork, especially during a dose change.

Step 2, Titrating: moving through 4 mg and 9 mg toward the 25 mg maintenance dose

Each escalation step requires a minimum of one month at the current dose before moving up. The ceiling is 25 mg daily. Patients who are already established on the 2.4 mg weekly injection may, subject to clinical assessment, move directly to the 25 mg tablet rather than restarting from 1.5 mg, but that decision sits with the prescriber, not with the patient.

The titration exists for a reason. Pushing through dose steps faster than the schedule allows does not speed up weight loss; it raises the risk of nausea and vomiting becoming severe enough to disrupt treatment altogether. Our prescribers at nume (sorry) at nume review progress before each dose increase, which is why there are no auto-renewals and no automated approvals. A real clinician reads your update every time.

For context on how the tablet compares with the injectable pathway, the full Wegovy treatment overview sets out both options side by side. If cost is a factor in your thinking, the Wegovy cost guide explains what private treatment typically includes and why headline prices vary between providers.

Step 3, Taking it correctly: the morning routine that determines how much is absorbed

Oral semaglutide absorption is sensitive to what surrounds it. The tablet must be taken first thing in the morning, on a completely empty stomach, with no more than about 120 ml of plain water. Swallow it whole. Then wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking other oral medicines.

That 30-minute window is not a rough guideline, it is the condition under which the clinical trials measured efficacy. Breaking it consistently reduces the amount of semaglutide that reaches your bloodstream, which in turn reduces how much the treatment can do. The difference between the 13.6% average weight loss and the roughly 17% seen among fully adherent participants in the OASIS 4 trial likely reflects exactly this kind of real-world variation in how carefully the instructions were followed.

No refrigeration is required, which makes the tablet straightforwardly travel-friendly. Keep it at room temperature, away from direct heat. For the exact storage conditions and a full list of contraindications, the prescribing information for Wegovy covers contraindications and storage conditions in full. If you want to understand more about semaglutide as a medicine before starting, our semaglutide information page covers the broader context.

Who the Wegovy pill is licensed for, and what the MHRA approval means

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The tablet is not licensed for people under 18, and it is not recommended during pregnancy, whilst breastfeeding, or when trying to conceive.

The June 2026 approval also means the Wegovy pill is not yet appraised by NICE, so NHS prescribing is not available at launch, it is currently a private prescription only. That may change in time, but for now the route to treatment is a private consultation with a regulated prescriber. The MHRA's approval as the UK's regulatory authority for medicines confirms the tablet meets the safety and efficacy standards required for use in adults, which is a meaningful bar.

One important distinction: Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes management at doses of 3 mg, 7 mg and 14 mg. Those strengths are not part of the Wegovy weight-loss schedule and should not be confused with it. If you hold a pilot's licence, it is also worth reading our guidance on whether pilots can take Wegovy before starting treatment. If you are exploring options and want to talk through whether the pill or the injection suits your situation better, starting a free consultation with our prescribers is the straightforward next step.